| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer
1 company
Cary J Claiborne is Chief Executive Officer at ADIL. Cary J Claiborne's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $204K at current prices.
Cary J Claiborne has 11 Form 4 filings on record from November 2021 to April 2026, across 2 companies: Chief Executive Officer at Adial Pharmaceuticals (ADIL), 2021–2026; Director at LadRx (LADX), 2024.
The 13 reported transactions were 8 option or other derivative awards and 5 stock awards.
There are no priced open-market purchases or sales on record, so none of these filings shows a decision to buy or sell shares in the market.
No transactions found
Try adjusting your filters or search criteria